Diego Roca - ForU Holdings Treasurer
| FORU Stock | USD 0.0001 0.00 0.00% |
Executive
Mr. Diego E. Roca is Chief Financial Officer of the Company. He has over 20 years of experience in financial management, operations, public filings, compliance, cash management and internal controls. From 1995 until 2004, he worked with Digitec 2000, Inc., a U.S. based telecommunications firm, where he began his career as Digitec Controller. He was promoted to Chief Operating Officer and finally Senior Vice President and Chief Financial Officer. From 2004 to 2006, Mr. Roca served as a consultant to various companies, including Digitec and Dominion Minerals Corporationration From 2007 to present he has held the office of Executive Vice President, Chief Financial Officer and Director for Dominion Minerals Corporationration an international mining firm with projects in the republics of China and Panama. From November 2013 to April 2014 and from August 2014 to October 2014, Mr. Roca served as the Chief Financial Officer and Chief Restructuring Officer, respectively, to Codesmart Holdings, Inc since 2015.
| Age | 56 |
| Tenure | 11 years |
| Phone | 732 536 1600 |
| Web | https://www.capsalus.com |
ForU Holdings Management Efficiency
The company has return on total asset (ROA) of (0.1504) % which means that it has lost $0.1504 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9885) %, meaning that it created substantial loss on money invested by shareholders. ForU Holdings' management efficiency ratios could be used to measure how well ForU Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Virginie MBA | DBV Technologies | 57 | |
| Sunil PharmD | Annexon | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Patrick Nealon | Aura Biosciences | N/A | |
| Lloyd MD | Annexon | N/A | |
| Alan Kerr | DBV Technologies | N/A | |
| Conor Kilroy | Aura Biosciences | 44 | |
| Gopi MBA | Larimar Therapeutics | 55 | |
| Stephanie Engels | Frequency Therapeutics | N/A | |
| Ravi Ramadas | Frequency Therapeutics | N/A | |
| Pharis MD | DBV Technologies | 61 | |
| Olukemi MD | Frequency Therapeutics | 50 | |
| Miriam Mason | Annexon | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| Todd Chappell | Frequency Therapeutics | 51 | |
| Jonathan Schwartz | Rocket Pharmaceuticals | 60 | |
| Shuli MD | Solid Biosciences LLC | N/A | |
| Vineet MBA | Frequency Therapeutics | 43 | |
| LLM JD | Rocket Pharmaceuticals | N/A | |
| Alexander Swan | Autolus Therapeutics | 60 | |
| Vesna Cizej | Autolus Therapeutics | N/A | |
Management Performance
| Return On Equity | -2.99 | |||
| Return On Asset | -0.15 |
ForU Holdings Management Team
Elected by the shareholders, the ForU Holdings' board of directors comprises two types of representatives: ForU Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ForU. The board's role is to monitor ForU Holdings' management team and ensure that shareholders' interests are well served. ForU Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ForU Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Lazar, President, CEO | ||
| Diego Roca, Treasurer | ||
| Steven Grubner, President Interim CEO, COO, Secretary |
ForU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ForU Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.99 | |||
| Return On Asset | -0.15 | |||
| Current Valuation | 3.61 M | |||
| Shares Outstanding | 2.58 M | |||
| Price To Earning | (0.08) X | |||
| Price To Sales | 1.40 X | |||
| EBITDA | (2.49 M) | |||
| Net Income | (16.03 M) | |||
| Cash And Equivalents | 4.04 K | |||
| Total Debt | 1.45 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ForU Pink Sheet Analysis
When running ForU Holdings' price analysis, check to measure ForU Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ForU Holdings is operating at the current time. Most of ForU Holdings' value examination focuses on studying past and present price action to predict the probability of ForU Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ForU Holdings' price. Additionally, you may evaluate how the addition of ForU Holdings to your portfolios can decrease your overall portfolio volatility.